share_log

Apollomics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)

Apollomics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)

Apollomics | F-3/A：交易注册声明（修正）
美股SEC公告 ·  04/19 16:13
Moomoo AI 已提取核心信息
Apollomics Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The Cayman Islands-based company, with operations in the U.S. and China, is preparing for the potential sale of securities to the public. The registration includes Class A ordinary shares and warrants, with the exact number and price yet to be determined. The securities may be sold from time to time in one or more offerings, and the proceeds are intended for general corporate purposes. This filing allows Apollomics to maintain an effective registration statement, facilitating future securities offerings. The company has not declared any cash dividends on its shares and does not anticipate doing so in the foreseeable future. Apollomics has obtained a 20-year tax concession from the Cayman Islands government, ensuring no tax on profits, income, gains, or appreciations. The company's Class A ordinary shares and warrants are listed on Nasdaq under the symbols 'APLM' and 'APLMW,' respectively.
Apollomics Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The Cayman Islands-based company, with operations in the U.S. and China, is preparing for the potential sale of securities to the public. The registration includes Class A ordinary shares and warrants, with the exact number and price yet to be determined. The securities may be sold from time to time in one or more offerings, and the proceeds are intended for general corporate purposes. This filing allows Apollomics to maintain an effective registration statement, facilitating future securities offerings. The company has not declared any cash dividends on its shares and does not anticipate doing so in the foreseeable future. Apollomics has obtained a 20-year tax concession from the Cayman Islands government, ensuring no tax on profits, income, gains, or appreciations. The company's Class A ordinary shares and warrants are listed on Nasdaq under the symbols 'APLM' and 'APLMW,' respectively.
处于临床阶段的生物制药公司Apollomics Inc. 已于2024年4月19日向美国证券交易委员会（SEC）提交了其F-3表格注册声明的修正案。这家总部位于开曼群岛的公司在美国和中国开展业务，正在为可能向公众出售证券做准备。注册包括A类普通股和认股权证，具体数量和价格尚未确定。证券可以不时通过一次或多次发行出售，所得款项用于一般公司用途。该文件允许Apollomics保留有效的注册声明，为未来的证券发行提供便利。该公司尚未宣布其股票的任何现金分红，预计在可预见的将来也不会这样做。Apollomics已获得开曼群岛政府为期20年的税收优惠，确保对利润、收入、收益或增值不征税。该公司的A类普通股和认股权证分别在纳斯达克上市，代码分别为 “APLM” 和 “APLMW”。
处于临床阶段的生物制药公司Apollomics Inc. 已于2024年4月19日向美国证券交易委员会（SEC）提交了其F-3表格注册声明的修正案。这家总部位于开曼群岛的公司在美国和中国开展业务，正在为可能向公众出售证券做准备。注册包括A类普通股和认股权证，具体数量和价格尚未确定。证券可以不时通过一次或多次发行出售，所得款项用于一般公司用途。该文件允许Apollomics保留有效的注册声明，为未来的证券发行提供便利。该公司尚未宣布其股票的任何现金分红，预计在可预见的将来也不会这样做。Apollomics已获得开曼群岛政府为期20年的税收优惠，确保对利润、收入、收益或增值不征税。该公司的A类普通股和认股权证分别在纳斯达克上市，代码分别为 “APLM” 和 “APLMW”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息